BACKGROUND INFORMATION
Education:
- Doctor of Veterinary Medicine, Iowa State University, 1985
Employment:
Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO (2003 to 2014)
- Oversaw and assisted with study design and protocol development, implementation of studies and writing of final reports for clinical and non-clinical studies (efficacy and safety) to aid in the licensure of new biological products (EU and USDA) and reference qualification of currently licensed biological products
- Located, interviewed, trained and consulted with Study Investigators and Contract Research Organizations
- Managed the Bio Clinical Development team with respect to research and pivotal clinical studies (safety and efficacy)
- Managed timelines and budgets of multiple projects
Colorado Serum Company, Denver, CO (1990 to 2002)
- Liaised with independent research laboratories to evaluate the market potential of new vaccines, and recommended which products had the potential to proceed to research and development
- Designed, implemented and monitored clinical studies (safety and efficacy) to aid in the licensure of new biological products and defend currently licensed products
- Manager of Technical Services and Manager of Clinical Studies; assisted with Regulatory Affairs
- Supervised animal care staff
- Directed antisera production
- Served as Attending Veterinarian for company IACUC
- Study Investigator for in-house clinical studies
Huron Animal Hospital Denver, CO (1985 to 1990)
- Associate veterinarian at a busy small animal hospital and served as primary soft tissue and orthopedic surgeon
Publications, Posters and Presentations:
- “An overview of a commercially available vaccine for Corynebacterium pseudotuberculosis”, USAHA, Sheep and Goat Committee, Louisville, Kentucky, 1997
- “Vaccines for goats”, American Dairy Goat Association Convention; Tucson,
Arizona, 1997
- Piontkowski MD, Shivvers DW. Evaluation of a commercially available vaccine against Corynebacterium pseudotuberculosis for use in sheep. J Am Vet Med Assoc, 1998 212:1765-1768.
- “Progress in vaccination against bovine brucellosis: a new vaccine RB51, which does not react in standard serological tests”, National Seminar on Brucellosis of Cattle, Sheep and Goats; Rabat, Morocco, 1998
- “US experiences with RB51”, OIE IV Seminar on Harmonization for registration and control of veterinary medicines; Salvador, Brazil, 1998
- Participant on panel “PAHO/WHO Expert consultation on Brucellosis vaccines and vaccine strategies for Brucellosis control/eradication programs”; Santiago, Chile, 1999
- Eichmeyer M, Roof M, Piontkowski M, Hayes P, Saltman R. “Efficacy evaluation of a Mycoplasma Hyopneumoniae Bacterin in a mixture with a Porcine Circovirus Type 2 Vaccine”. 20th IPVS Congress, Durban, South Africa, 22-26 June 2008
- Piontkowski, M, Ohnesorge C, I von Richthofen. “Ingelvac MycoFLEX® provides at least 26 weeks duration of immunity”. 2008 Lehman Conference, St. Paul, MN, 20-23 September 2008
- Piontkowski, M, Eichmeyer M. “Multi-site field safety study of a trivalent vaccine mixture”. 2010 Lehman Conference, St. Paul MN, 19-21 September 2010
- Eichmeyer M, Roof M, Piontkowski M, Robb E. “Efficacy of Ingelvac® PRRS MLV when rehydrated with a combination of Ingelvac® MycoFLEX™ and Ingelvac® CircoFLEX™. 2010 Lehman Conference, St. Paul MN, 19-21 September 2010
- Glover S, Anderson C, Piontkowski M, Ng T. Canine Parvovirus (CPV) Type 2b vaccine protects puppies with maternal antibodies to CPV when challenged with virulent CPV-2c virus. Intern J Appl Res Vet Med, 2012 10:217-224.
Patents:
- US Patent No.: 8,765,142
- US Patent No.: 8,865,183
- EU Patent No.: EP2675475
- EU Patent No.: EP2481420
- EU Patent No.: EP2094872
Professional Affiliations:
- American Association of Veterinary Immunologists
- American Veterinary Medical Association
- Kansas Veterinary Medical Association
State Veterinary Licenses:
- Kansas
- Colorado